Product
Bupivacaine HCl
Aliases
0.25 % Bupivacaine HCl, Bupivacaine HCl 0.5% Injectable Solution
Name
Bupivacaine HCl
INN Name
BUPIVACAINE HCl
FDA Approved
Yes
5 clinical trials
2 organizations
11 indications
1 document
Indication
Postoperative PainIndication
Postherpetic NeuralgiaIndication
MigraineIndication
Diaphragmatic ParalysisIndication
Diaphragma sellae meningiomaIndication
ComplicationsIndication
Respiratory ComplicationIndication
Nerve BlockIndication
Brachial Plexus BlockIndication
PainIndication
PostoperativeClinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group Study of the Efficacy and Safety of a Single Administration of F14 for Postoperative Analgesia in Patients Undergoing Unilateral Total Knee ReplacementStatus: Active (not recruiting), Estimated PCD: 2023-11-22
Clinical trial
Parallel Study to Evaluate the Pharmacokinetics, Dose Proportionality, Safety and Tolerability of GTX-101 (Bupivacaine Hydrochloride Metered Dose Spray) and Subcutaneous Injectable Bupivacaine in Healthy SubjectsStatus: Active (not recruiting), Estimated PCD: 2022-08-21
Clinical trial
Efficacy of Peripheral Nerve Blocks for Episodic Migraine Treatment and ProphylaxisStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening FractionStatus: Completed, Estimated PCD: 2021-08-15
Clinical trial
Comparing the Efficacy of a Periarticular Instillation of Extended Relief Bupivacaine and Meloxicam With Routine Adductor Canal Blockade for Pain Relief After Primary TKAStatus: , Estimated PCD: 2024-02-28
Document
DailyMed Label: Bupivacaine HClOrganization
Xellia Pharmaceuticals USA LLCOrganization
HF Acquisition Co LLC, DBA HealthFirst